Rhondalyn McLean

Rhondalyn McLean

Auto-generated profile, based on publicly available information

Rhondalyn McLean

University of Pennsylvania, Philadelphia, PA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2016 in Case Reports in Cardiology
Verified
Journal Article
Open access
PDF file
DLDaniel Lu
Daniel Lu
JCJulie Caplow
Julie Caplow
NQNeha Quatromoni
Neha Quatromoni
RFRhondalyn Forde-McLean
Rhondalyn Forde-McLean
AOAnjali Tiku Owens
Anjali Tiku Owens
Takotsubo Syndrome is a transient condition characterized by left ventricular systolic dysfunction with apical akinesis/dyskinesis and ballooning. Although the prognosis with medical management is excellent in most cases, rare cases of serious complications can occur. We present here a case of a 71-year-old woman presenting with acute decompensated heart failure with initial findings consistent with a myocardial infarction, who was found instead to have an acute ventricular septal defect as a complication of Takotsubo Syndrome.

1 April 2017 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
PDF file
MPM. Palardy
M. Palardy
RMR. McLean
R. McLean
SPS. Pamboukian
S. Pamboukian
MKMichelle M. Kittleson
Michelle M. Kittleson
LSL. Warner Stevenson
L. Warner Stevenson
FIF. REVIVAL Investigators
F. REVIVAL Investigators

5 March 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
LHLuise Holzhauser
Luise Holzhauser
NRNosheen Reza
Nosheen Reza
JEJonathan J. Edwards
Jonathan J. Edwards
EBEdo Y Birati
Edo Y Birati
AOAnjali Tiku Owens
Anjali Tiku Owens
JEJonathan B. Edelson
Jonathan B. Edelson
Background: Annual heart transplant (HT) volumes have increased, as have post‐HT outpatient care needs. Data on HT‐related emergency department (ED) visits are limited. Methods and Results: A retrospective analysis of 177 450 HT patient ED visits from the 2009 to 2018 Nationwide Emergency Department Sample was conducted. HT recipients, primary diagnoses, and comorbidities associated with ED visits were identified via International Classification of Diseases, Ninth Revision ( ICD‐9 ) and International Classification of Diseases, Tenth Revision ( ICD‐10 ) codes. Multivariable logistic regression was used to predict outcomes of hospital admission and death. HT volumes and HT‐related ED visits increased from 2009 to 2018. Infection was the most common primary diagnosis (24%), and cardiac primary diagnoses represented 10% of encounters. Hospital admissions occurred in 48% of visits, but overall mortality was low (1.6%). Length of stay was 3.1 days (interquartile range, 1.6–5.9 days), and comorbidity burden was high: 42% had hypertension, 38% had diabetes, and 31% had ≥2 comorbidities. Those aged ≥65 years had significantly higher odds of admission (odds ratio [OR], 2.14 [95% CI, 1.97–2.33]) and death (OR, 2.06 [95% CI, 1.61–2.62]). Comorbidities increased odds of admission (OR, 1.62 [95% CI, 1.51–1.75]) but not death. Renal primary diagnosis had the highest risk of admission (OR, 4.1 [95% CI, 3.6–4.6]), but cardiac primary diagnosis had the highest odds of death (OR, 11.6 [95% CI, 9.1–14.8]). Conclusions: HT‐related ED visits increased from 2009 to 2018 with high admission rates but low in‐hospital mortality, suggesting an opportunity to improve prehospital care. Older patients and those with cardiac primary diagnoses had the highest risk of death. The observed contrast between predictors of admission and mortality signals a need for further study to improve risk stratification and outpatient care strategies.

3 April 2024 in Clinical Transplantation
Verified
Journal Article
Open access
LHLuise Holzhauser
Luise Holzhauser
MNMaxwell Norris
Maxwell Norris
MMMaria Molina
Maria Molina
SCSusan Chambers
Susan Chambers
SSSwethika Sundaravel
Swethika Sundaravel
EPEliot Peyster
Eliot Peyster
Background: The use of induction immunosuppression for heart transplantation (HT) is debated given the uncertain benefit and potential risks of infection and malignancy.Methods: This is a retrospective single‐center analysis of 475 consecutive HT recipients from 2003 to 2020 grouped by use of induction with basiliximab group (BG) and the no basiliximab group (NBG). Subgroup analysis by era compared pre‐2016 standard‐basiliximab (BX) induction and 2016–2020 with selective‐BX use as part of a calcineurin‐inhibitor‐sparing regimen.Results: When adjusted for confounders (sex, age, PRA, eGFR), the BG was less likely to have acute cellular rejection (ACR) (OR.42, p < .001), but had more antibody mediated rejection (AMR) (OR 11.7, p < .001) and more cardiac allograft vasculopathy (CAV) (OR 3.8, p = .04). There was no difference between BG and NBG in the incidence of malignancies or infections. When stratified by era (pre‐2016 vs. 2016–2020), ACR remained less common in the BG than the NBG (36% vs. 50%, p = .045) groups, while AMR remained more common (9.7 vs. 0% p = .005). There was no significant difference in conditional survival comparing pre‐and post‐2016 NBG (HR 2.20 (95% CI.75–6.43); however, both pre‐2016 BG and post‐2016 BG have significantly higher mortality (HR 2.37 [95% CI 1.02–5.50) and HR 2.69 (95% CI 1.08–6.71), p = .045 and.03, respectively].Conclusion: Basiliximab reduces the incidence of ACR but increases the risk of AMR, CAV, and may be associated with increased mortality. Mechanistic studies are needed to describe a potential T‐cell‐escape mechanism with enhanced humoral immunity.

28 April 2022 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
LHLuise Holzhauser
Luise Holzhauser
MNMaxwell Norris
Maxwell Norris
MMMaria Molina
Maria Molina
THThomas Hanff
Thomas Hanff
SCSusan Chambers
Susan Chambers
RMRhondalyn McLean
Rhondalyn McLean